Possible mechanism involved in the anticonvulsant action of butorphanol in mice

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 2, 2003, Pages 343-350

  Manocha, Anshu ^a,b   Sharma, Krishna Kishore ^a   Mediratta, Pramod Kumari ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b E 99 ^*  (India)

Author keywords

Aminobutyric acid; Butorphanol; Convulsions; Maximal electroshock; N Methyl D aspartate; Opioids

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 5 AMINOVALERIC ACID; 5,9 DIETHYL 2 (3 FURYLMETHYL) 2' HYDROXY 6,7 BENZOMORPHAN; BACLOFEN; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BUTORPHANOL; DIAZEPAM; DIZOCILPINE; FLUMAZENIL; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NALTRINDOLE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; ELECTRIC SHOCK; ELECTRODE; FEMALE; HINDLIMB; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; STATISTICAL ANALYSIS;

ANALGESICS, OPIOID; ANIMALS; ANTICONVULSANTS; BENZOMORPHANS; BUTORPHANOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEMALE; LIGANDS; MALE; MICE; NALOXONE; NARCOTIC ANTAGONISTS; RECEPTORS, GABA-A; RECEPTORS, GABA-B;

EID: 0037212447     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01004-3     Document Type: Article

References (41)

1. Atapour N., Kalantaripour T.P., Nourpanah M., Niazi M. Chemical kindling and seizure susceptibility in morphine dependent rats. Eur. Neuropsychopharmacol. 10:2000;483-487.
2. B receptor pharmacology. Annu. Rev. Pharmacol. Toxicol. 33:1993;109-147.
3. Brogden R.N., Goa K.L. Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs. 42:1991;1061-1089.
4. Broom D.C., Gno L., Coop A., Husbands S.M., Lewis J.W., Woods J.H.et al. BU48: a novel buprenorphine analog that exhibits delta-opioid mediated convulsions but not delta-opioid-mediated antinociception in mice. J. Pharmacol. Exp. Ther. 294:2000;1195-1200.
5. Coimbra N.C., Castro-Souza C., Segato E.N., Nora J.E., Herrero C.F., Tedeschi-Filho W.et al. Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res. 888:2001;314-320.
6. Coimbra N.C., Freitas R.L., Savoldi M., Castro-Souza C., Segato E.N.K.R., Weltson A.et al. Opioid neurotransmission in the post-ictal analgesia: involvement of mu(1)-opioid receptor. Brain Res. 903:2001;216-221.
7. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S.et al. International Union of Pharmacology: XII. Classification of opioid receptors. Pharmacol. Rev. 48:1996;567-592.
8. Dingledine R., Iversen L.L., Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur. J. Pharmacol. 47:1978;19-27.
9. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of neuropsychopharmacology. 1997;Sinauer, Sunderland (MA).
10. Fischer W., Bodewei R., VonVoigtlander P.F., Müller M. Anticonvulsant and related effects of U-54494A in various seizure tests. J. Pharmacol. Exp. Ther. 267:1993;163-170.
11. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res. Rev. 6:1983;197-210.
12. Frey H.-H. Effect of μ- and κ-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR2266. Pharmacol. Toxicol. 62:1988;150-154.
13. Gillis J.C., Benfield P., Goa K.L. Transnasal butorphanol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs. 50:1995;157-175.
14. Gupta S.P. Statistical methods. 25th ed. 1990;Sultan Chand Publishers, India.
15. Horan P., Ho I.K. Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol. Biochem. Behav. 34:1989;847-854.
16. A receptor pharmacology. Pharmacol. Ther. 69:1996;173-198.
17. Laorden M.L., Carrillo E., Puig M.M. Prevention of hyperthermia-induced convulsions in immature rat by MR-2266, a kappa antagonist. Methods Find. Exp. Clin. Pharmacol. 13:1991;605-608.
18. Lauretti G.R., Ahmad I., Pleuvry B.J. The activity of opioid analgesics in seizure models utilizing N-methyl-DL-aspartic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology. 33:1994;155-160.
19. 35S]-t-butylbicyclophosphorothionate binding differentiates convulsant and depressant drugs that modulate GABAergic transmission. J. Neurochem. 44:1985;480-486.
20. Manocha A., Sharma K.K., Mediratta P.K. The anticonvulsant effect of pentazocine against maximal electroshock seizure in mice. Indian J. Pharmacol. 29:1997;194-197.
21. Manocha A., Sharma K.K., Mediratta P.K. Anticonvulsant effect of nalbuphine on maximal electroshock seizure in mice. Indian J. Pharmacol. 30:1998;306-310.
22. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 11:1988;308-314.
23. Matsumoto R.R. GABA receptors: are cellular differences reflected in function? Brain Res. Rev. 14:1989;203-225.
24. Meldrum B.S. Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res. 12:1992;189-196.
25. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 178:1972;984-986.
26. Paredes R.G., Ågmo A. GABA and behavior: the role of receptor subtypes. Neurosci. Biobehav. Rev. 16:1992;145-170.
27. Pircio A.W., Gylys J.A., Cavanagh R.L., Buyniski J.P., Bierwagen M.E. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch. Int. Pharmacodyn. 220:1976;231-257.
28. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. 1996;521-555 McGraw-Hill, New York.
29. Rogawski M.A. Mechanism-specific pathways for new antiepileptic drug discovery. French J., Leppik I., Dichter M.A. Antiepileptic drug development. Advances in Neurology. vol. 76:1998;11-27 Lippincott-Raven Publishers, Philadelphia (PA).
30. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
31. Schwarz M., Klockgether T., Wüllner U., Turski L., Sontaq K.-H. δ-Aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system. Exp. Brain Res. 70:1988;618-626.
32. Swinyard E.A., Brown W.C., Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 106:1952;319-330.
33. 2: application to the analgesic effect of morphine. J. Pharmacol. Exp. Ther. 206:1978;38-45.
34. Tortella F.C. Endogenous opioid peptides and epilepsy: quieting the seizing brain? Trends Pharmacol. Sci. 9:1988;366-372.
35. Tortella F.C., Robles L., Holaday J.W. U50,488, a highly selective kappa opioid: anticonvulsant profile in rats. J. Pharmacol. Exp. Ther. 237:1986;49-53.
36. Uhl G.R., Childers S., Pasternak G. An opiate-receptor gene family reunion. Trends Neurosci. 17:1994;89-93.
37. White H.S., Wolf H.H., Woodhead J.H., Kupferberg H.J. The national institutes of health anticonvulsant drug development program: screening for efficacy. French J., Leppik I., Dichter M.A. Antiepileptic drug development, Vol. 76. Advances in neurology. 1998;29-39 Lippincott-Raven Publishers, Philadelphia (PA).
38. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. Drugs. 55:1998;1-4.
39. Wong E.H.F., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7104-7108.
40. Yajima Y., Narita M., Takahashi-Nakano Y., Misawa M., Nagase H., Mizoguchi H.et al. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res. 862:2000;120-126.
41. Zieglgansberger W., French E.D., Siggins G.R., Bloom F.E. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science. 205:1979;415-417.